Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis.

Phase 1 Completed 60 enrolled Sunshine Lake Pharma Co., Ltd. Nicoya Therapeutics (Shanghai) Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HEC53856 capsules on anemia in subjects with chronic kidney disease on dialysis.

Timeline

Start: 2021-09-10
Primary completion: 2022-10-19
Completion: 2022-10-19

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HEC53856	Unknown	100 mg	Oral
Subject	HEC53856	Unknown	150 mg	Oral
Subject	HEC53856	Unknown	200 mg	Oral

Indications

No indication recorded.